U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07414433) titled 'Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma' on Feb. 09.
Brief Summary: The goal of this prospective observational study is to validate the clinical utility of specific blood-based biomarkers for predicting and monitoring treatment response in patients with hepatocellular carcinoma (HCC) undergoing Transarterial Chemoembolization (TACE).
The study aims to determine if longitudinal changes in these biomarkers can reliably correlate with early radiological treatment response, as measured by Modified Response Evaluation Criteria in Solid Tumors (mRECIST). Participants will receive standard-of-care TAC...